Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Dow
Colorcon
McKinsey
Express Scripts

Last Updated: May 27, 2022

Fresenius Medcl Company Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Fresenius Medcl
International Patents:22
US Patents:3
Tradenames:22
Ingredients:5
NDAs:9

Drugs and US Patents for Fresenius Medcl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Medcl DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate SOLUTION;INTRAPERITONEAL 018379-006 Jul 7, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
Fresenius Medcl INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER calcium chloride; dextrose; sodium chloride; sodium lactate SOLUTION;INTRAPERITONEAL 019395-001 Mar 26, 1986 DISCN No No See Plans and Pricing See Plans and Pricing
Fresenius Medcl PHOSLO calcium acetate TABLET;ORAL 019976-001 Dec 10, 1990 DISCN Yes No See Plans and Pricing See Plans and Pricing
Fresenius Medcl DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate SOLUTION;INTRAPERITONEAL 018379-004 Jul 7, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
Fresenius Medcl DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate SOLUTION;INTRAPERITONEAL 018379-001 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
Fresenius Medcl PHOSLO GELCAPS calcium acetate CAPSULE;ORAL 021160-003 Apr 2, 2001 AB RX Yes Yes See Plans and Pricing See Plans and Pricing
Fresenius Medcl DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate SOLUTION;INTRAPERITONEAL 018883-004 Nov 30, 1984 AT RX Yes Yes See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Fresenius Medcl

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fresenius Medcl PHOSLO calcium acetate TABLET;ORAL 019976-001 Dec 10, 1990 4,870,105 See Plans and Pricing
Fresenius Medcl PHOSLO calcium acetate CAPSULE;ORAL 021160-002 Apr 2, 2001 6,576,665 See Plans and Pricing
Fresenius Medcl PHOSLO calcium acetate CAPSULE;ORAL 021160-001 Apr 2, 2001 4,870,105 See Plans and Pricing
Fresenius Medcl PHOSLO GELCAPS calcium acetate CAPSULE;ORAL 021160-003 Apr 2, 2001 6,875,445 See Plans and Pricing
Fresenius Medcl PHOSLO GELCAPS calcium acetate CAPSULE;ORAL 021160-003 Apr 2, 2001 6,576,665 See Plans and Pricing
Fresenius Medcl PHOSLO GELCAPS calcium acetate CAPSULE;ORAL 021160-003 Apr 2, 2001 4,870,105 See Plans and Pricing
Fresenius Medcl PHOSLO calcium acetate CAPSULE;ORAL 021160-002 Apr 2, 2001 4,870,105 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for FRESENIUS MEDCL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules EQ 169 mg calcium ➤ Subscribe 2005-05-31
➤ Subscribe Oral Solution 667 mg/5 mL ➤ Subscribe 2013-12-05

International Patents for Fresenius Medcl Drugs

Country Patent Number Estimated Expiration
South Korea 20090040340 See Plans and Pricing
Mexico 2009000722 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2008011126 See Plans and Pricing
Japan 2009544615 See Plans and Pricing
Spain 2382993 See Plans and Pricing
Israel 196584 See Plans and Pricing
New Zealand 574331 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Fresenius Medcl Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0521471 SPC/GB03/033 United Kingdom See Plans and Pricing PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
1856135 CA 2020 00018 Denmark See Plans and Pricing PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
0933372 13/2008 Austria See Plans and Pricing PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
0521471 C300125 Netherlands See Plans and Pricing PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106
2822954 1890030-8 Sweden See Plans and Pricing PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625
0579826 02C0041 France See Plans and Pricing PRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418
0933372 SPC/GB08/018 United Kingdom See Plans and Pricing PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
Baxter
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.